Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5051
Roadzen
RDZN
$104M
| $5 | ﹤0.01% |
2
| – | – |
2024 Q1
7 quarters
|
|
5052
INNOVATE Corp
VATE
$102M
| $5 | ﹤0.01% |
1
-173
| -99% | -$858 |
2023 Q1
11 quarters
|
|
5053
Workhorse Group
WKHS
$32.5M
| $5 | ﹤0.01% |
+1
| New | +$10 |
2024 Q4
4 quarters
|
|
5054
Metagenomi Therapeutics
MGX
$38.5M
| $5 | ﹤0.01% |
3
| – | – |
2024 Q2
6 quarters
|
|
5055
GrowGeneration
GRWG
$92.5M
| $4 | ﹤0.01% |
2
-195
| -99% | -$320 |
2020 Q2
22 quarters
|
|
5056
iBio
IBIO
$72.7M
| $4 | ﹤0.01% |
+2
| New | +$3 |
2025 Q4
0 quarters
|
|
|
SOPA
5057
DELISTED
Society Pass
SOPA
| $4 | ﹤0.01% |
+1
| New | +$2 |
2025 Q4
0 quarters
|
|
5058
Cibus
CBUS
$131M
| $3 | ﹤0.01% |
2
| – | – |
2024 Q1
7 quarters
|
|
5059
CDT Equity Inc
CDT
$763K
| – | – |
0
| – | – |
2025 Q4
0 quarters
|
|
5060
Full House Resorts
FLL
$50.9M
| $3 | ﹤0.01% |
1
| – | – |
2021 Q1
19 quarters
|
|
5061
Telomir Pharmaceuticals
TELO
$81.2M
| $3 | ﹤0.01% |
2
| – | – |
2024 Q2
6 quarters
|
|
|
TII
5062
Titan Mining Corp
TII
$242M
| $3 | ﹤0.01% |
+1
| New | +$3 |
2025 Q4
0 quarters
|
|
5063
Bridger Aerospace
BAER
$40M
| $2 | ﹤0.01% |
1
| – | – |
2024 Q2
6 quarters
|
|
5064
Drilling Tools International
DTI
$80.8M
| $2 | ﹤0.01% |
1
| – | – |
2024 Q2
6 quarters
|
|
|
IPHA
5065
Innate Pharma
IPHA
$174M
| $2 | ﹤0.01% |
1
-306
| -100% | -$591 |
2022 Q1
15 quarters
|
|
5066
Jasper Therapeutics
JSPR
$18.8M
| $2 | ﹤0.01% |
1
| – | – |
2024 Q2
6 quarters
|
|
|
OGI
5067
Organigram Holdings
OGI
$137M
| $2 | ﹤0.01% |
1
-1,700
| -100% | -$2.92K |
2022 Q1
15 quarters
|
|
5068
Outlook Therapeutics
OTLK
$144M
| $2 | ﹤0.01% |
1
| – | – |
2021 Q1
19 quarters
|
|
5069
Ovid Therapeutics
OVID
$465M
| $2 | ﹤0.01% |
1
-70
| -99% | -$108 |
2023 Q2
10 quarters
|
|
5070
Purple Innovation
PRPL
$9.16M
| – | – |
0
| – | – |
2025 Q3
1 quarter
|
|
5071
Quest Resource Holding
QRHC
$28.9M
| $2 | ﹤0.01% |
1
| – | – |
2024 Q2
6 quarters
|
|
5072
Swvl Holdings Corp Warrant
SWVLW
$106K
| $2 | ﹤0.01% |
238
| – | – |
2022 Q2
14 quarters
|
|
5073
XBiotech
XBIT
$66.8M
| $2 | ﹤0.01% |
1
-206
| -100% | -$508 |
2024 Q2
6 quarters
|
|
|
GCTS
5074
GCT Semiconductor Holding
GCTS
$207M
| $2 | ﹤0.01% |
2
| – | – |
2024 Q2
6 quarters
|
|
|
BOLD
5075
Boundless Bio
BOLD
$59.6M
| $2 | ﹤0.01% |
2
| – | – |
2024 Q1
7 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.